Compare KWY & NNNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KWY | NNNN |
|---|---|---|
| Founded | 1989 | 2021 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 283.2M | 270.4M |
| IPO Year | 2013 | 2023 |
| Metric | KWY | NNNN |
|---|---|---|
| Price | $9.40 | $6.30 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 29.4K | ★ 228.0K |
| Earning Date | 11-05-2026 | 10-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $134,996,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $446.57 |
| Revenue Growth | ★ 23.42 | N/A |
| 52 Week Low | $8.41 | $5.13 |
| 52 Week High | $11.36 | $51.33 |
| Indicator | KWY | NNNN |
|---|---|---|
| Relative Strength Index (RSI) | 45.05 | 43.64 |
| Support Level | $8.41 | $5.13 |
| Resistance Level | $9.60 | $6.95 |
| Average True Range (ATR) | 0.33 | 0.52 |
| MACD | -0.02 | 0.21 |
| Stochastic Oscillator | 39.34 | 66.48 |
Kingsway Corp is a U.S.-based company employing the Search Fund model to acquire and build great businesses. The company owns and operates a collection of B2B and B2C services companies that are asset-light, growing, profitable, and that have recurring revenues. It seeks to compound long-term shareholder value on a per share basis via its decentralized management model, its talented team of operators, and its tax-advantaged corporate structure.
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. The company's mission is to change the diagnostics market by personalizing and decentralizing the current diagnostic solutions for faster diagnosis to improve patient prognosis. The company proposes this by providing accessible and affordable diagnostic solutions globally at the forefront of science and offering laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions. The business planning is to focus on validating and commercializing the existing portfolio of in vitro diagnostic products, as well as generating additional data required to support regulatory submissions and compliance, including under frameworks such as the In Vitro Diagnostic Regulation (IVDR).